

---

## Press Release

---

March 28, 2025

Sumitomo Pharma Co., Ltd.

### **Notice Regarding the Transfer of Shares of Subsidiary**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced today that the Company has entered into an agreement, effective March 28, 2025, to transfer all shares of its wholly owned subsidiary, FrontAct Co., Ltd. (hereinafter “FrontAct”), to Sawai Group Holdings Co., Ltd. (Head Office: Osaka, Japan; Representative Director, Chairman and President: Mitsuo Sawai; hereinafter “Sawai Group Holdings”).

#### 1. Reason for the Share Transfer

The Company is working on various measures to achieve early business recovery and renewed growth, aiming to transform fiscal 2024 into a turning point for the growth of the Company group. FrontAct has been engaged in Frontier Business, aiming to deliver innovative solutions that address social challenges in the healthcare sector beyond pharmaceuticals.

For further expansion and accelerated growth of FrontAct, the Company has decided to transfer its shares, considering that Sawai Group Holdings, with expertise in digital healthcare business, will be the best owner to strengthen FrontAct's competitiveness.

#### 2. Overview of FrontAct

(1)	Company name	FrontAct Co., Ltd.
(2)	Location	17-24, Shinkawa 1-Chome, Chuo-ku, Tokyo, NMF Kayabacho Building 5F
(3)	Name and Title of Representative	Takehiko Nomura, Representative Director, President and CEO
(4)	Business	Research, development, manufacturing, sales and marketing, leasing, and export and import of products, software, and systems, including but not limited to medical care, nursing care, welfare, health, and daily living
(5)	Established	April 1, 2024
(6)	Capital	100 million JPY
(7)	Major Shareholders and Shareholding Ratio	The Company 100%

#### 3. Overview of Sawai Group Holdings

(1)	Company name	Sawai Group Holdings Co., Ltd.
(2)	Location	5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan
(3)	Name and Title of Representative	Mitsuo Sawai, Representative Director, Chairman and President
(4)	Business	Holding company carrying out group management control

		and conducting related duties
(5)	Established	April 1, 2021
(6)	Capital	10 billion JPY

#### 4. Future Outlook

The impact of this share transfer on the Company's consolidated financial results for the fiscal year ending March 2025 is expected to be minimal. The transfer is scheduled to be completed in the end of June 2025, following the necessary procedures.

#### Contact:

Corporate Communications,

Global Finance

Sumitomo Pharma Co., Ltd.

E-mail: [prir@sumitomo-pharma.co.jp](mailto:prir@sumitomo-pharma.co.jp)